Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
Want to see GB:POLB full AI Analyst Report?
Top Page
Poolbeg Pharma Ltd.
(LSE:POLB)
Select Model
Select Model
Rating:55Neutral
Price Target:
5.00 p
▲(40.85% Upside)
Action:Reiterated
Date:05/09/26
Overall score reflects a tug-of-war between weak financial performance (pre-revenue, ongoing losses and cash burn, shrinking equity) and a comparatively strong earnings-call backdrop with tangible regulatory/clinical progress and identifiable upcoming catalysts. Technical signals are neutral-to-slightly positive, while valuation is not supportive due to negative earnings and no dividend data.
Positive Factors
TOPICAL program ready with regulatory and operational setup
Regulatory approval plus site, CRO and in-kind supply from J&J materially lowers execution risk and operational barriers for the POLB‑001 TOPICAL study. This readiness accelerates data generation capability, strengthens partner confidence, and improves the company's ability to reach clinical inflection points without manufacturing hold-ups.
Negative Factors
Pre‑revenue with sustained losses and cash burn
The company is pre‑revenue and has recorded recurring net losses with operating cash outflows worsening over multiple years. Persistent negative free cash flow reduces internal funding capacity, increases reliance on external financing, and constrains long‑term flexibility to fund larger confirmatory studies or commercialization without dilutive raises or partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
TOPICAL program ready with regulatory and operational setup
Regulatory approval plus site, CRO and in-kind supply from J&J materially lowers execution risk and operational barriers for the POLB‑001 TOPICAL study. This readiness accelerates data generation capability, strengthens partner confidence, and improves the company's ability to reach clinical inflection points without manufacturing hold-ups.
Read all positive factors
Poolbeg Pharma Ltd. (POLB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£33.84M
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue GrowthN/A
EPS Growth19.83%
CountryUK
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Poolbeg Pharma Ltd. Business Overview & Revenue Model
Company Description
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intran...
How the Company Makes Money
Poolbeg Pharma Ltd. does not primarily generate revenue from product sales because it is a clinical-stage company without marketed drugs; detailed, up-to-date product-revenue figures are not available in this response. Its expected/typical ways of...
Poolbeg Pharma Ltd. Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 08, 2026
Earnings Call Sentiment Positive
The call conveyed strong progress across regulatory, IP, preclinical/clinical readiness and partnership engagement, supported by concrete metrics (GBP 7.7m cash, GBP 4.865m fundraising, GBP 3.4m grant, Orphan Drug designation, patents, ~85%–95% cytokine inhibition in LPS model). Key upcoming inflection points (TOPICAL interim readout expected summer 2026; oral GLP-1 trial in H2 2026) underpin near-term value catalysts. Offset risks include a manufacturing delay for the GLP-1 program, a small open-label TOPICAL study requiring further confirmatory work, dependence on partners for late-stage development/commercialization, and a funding runway limited to 2027. On balance, highlights materially outweigh lowlights given the substantive regulatory milestones, strong early efficacy signals, payer interest and active partnering — suggesting positive momentum ahead of the summer data readout.Positive Updates
Clinical Progress — TOPICAL (POLB 001) Ready to Start
MHRA approval obtained, protocol finalized, 6 UK sites secured (The Christie, UCH, Royal Marsden, Birmingham, NHS North Midlands/Royal Stoke, Edinburgh), ACT appointed as CRO, J&J supplying teclistamab at no cost, patient recruitment and dosing imminent for ~30 relapsed/refractory multiple myeloma patients.
Negative Updates
GLP-1 Program Manufacturing Delay
Start of the oral GLP-1 clinical trial deferred to the second half of 2026 due to revised manufacturing lead times, delaying the anticipated timeline for proof-of-concept readout.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Progress — TOPICAL (POLB 001) Ready to Start
MHRA approval obtained, protocol finalized, 6 UK sites secured (The Christie, UCH, Royal Marsden, Birmingham, NHS North Midlands/Royal Stoke, Edinburgh), ACT appointed as CRO, J&J supplying teclistamab at no cost, patient recruitment and dosing imminent for ~30 relapsed/refractory multiple myeloma patients.
Read all positive updates
Company Guidance
Management guided that Poolbeg has financial runway into 2027 (cash £7.7m at FY2025, following a £4.865m fundraising and with a £3.4m RISE grant), that the POLB‑001 TOPICAL CRS‑prevention trial is fully prepared (MHRA approval, ACT as CRO, J&J supplying teclistamab at no cost) and will enroll ~30 relapsed/refractory multiple myeloma patients across 6 U.K. sites with twice‑daily dosing around the 5–8 day step‑up teclistamab period (when ~96–100% of CRS occurs), with interim data expected in summer 2026; this builds on a Phase Ib LPS human challenge (30/70/150 mg BID) showing dose‑response and ~85–95% suppression of IL‑6/IL‑8 (p38 inhibition ~80–90%). They reiterated a >$10bn U.S./EU5 market opportunity (modeled from ~500,000 patients 2023–2030 and an illustrative ~$20,000 price point vs Neulasta’s ~$18,000), noted >70% CRS incidence with some T‑cell engagers, Grade‑3 CRS management costs >$70,000, patent coverage to at least 2044, and that an oral GLP‑1 PK/safety study in 20 volunteers is planned for H2 2026.Poolbeg Pharma Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -114.00K | -26.00K | -26.00K | -18.00K |
| EBITDA | -6.42M | -6.00M | -4.66M | -4.75M | -2.32M |
| Net Income | -5.70M | -5.79M | -3.93M | -4.69M | -2.34M |
Balance Sheet | |||||
| Total Assets | 9.94M | 10.25M | 15.43M | 19.29M | 23.02M |
| Cash, Cash Equivalents and Short-Term Investments | 7.71M | 7.82M | 12.17M | 16.19M | 20.95M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.34M | 974.00K | 986.00K | 966.00K | 438.00K |
| Stockholders Equity | 8.60M | 9.27M | 14.44M | 18.32M | 22.58M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -4.78M | -4.02M | -4.96M | -2.23M |
| Operating Cash Flow | -4.51M | -4.65M | -3.85M | -4.37M | -2.15M |
| Investing Cash Flow | -80.00K | 299.00K | 359.00K | -388.00K | -81.00K |
| Financing Cash Flow | 4.48M | 0.00 | 0.00 | 0.00 | 23.18M |
Poolbeg Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £33.84M | -4.23 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £29.10M | -3.13 | -202.14% | ― | ― | -105.65% | |
53 Neutral | £51.63M | -1.83 | -14.65% | 2.94% | -25.43% | -155.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £26.83M | -3.00 | -6634.51% | ― | ― | ― | |
42 Neutral | £45.83M | -1.82 | -3931.14% | ― | ― | -28.29% | |
40 Underperform | £19.87M | -6.19 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:POLB
Poolbeg Pharma Ltd.
4.80
2.20
84.62%
GB:IMM
ImmuPharma
4.52
1.66
58.32%
GB:SAR
Sareum Holdings
21.00
5.00
31.25%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
677.50
500.00
281.69%
GB:HVO
Open Orphan Plc
7.95
-9.55
-54.57%
GB:APTA
Aptamer Group Plc
0.58
0.21
59.72%
Poolbeg Pharma Ltd. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Poolbeg to Showcase POLB 001 CRS Data at Major Hematology Congress
Positive
May 13, 2026
Poolbeg Pharma said it will present new data on its lead candidate POLB 001 at the European Hematology Association Congress in Stockholm in June 2026. The compound is an oral p38 MAPK inhibitor being developed to prevent cancer immunotherapy-induc...
Business Operations and Strategy
Poolbeg Pharma Wins Canadian Patent for POLB 001 in Cancer CRS Prevention
Positive
May 11, 2026
Poolbeg Pharma has secured a Canadian patent covering the use of p38 MAPK inhibitors, including its lead candidate POLB 001, to prevent cancer immunotherapy-induced Cytokine Release Syndrome, reinforcing its intellectual property position in oncol...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Poolbeg Pharma Publishes 2025 Annual Report and Sets June AGM Date
Positive
May 7, 2026
Poolbeg Pharma has published its Annual Report and Accounts for the year ended 31 December 2025 and dispatched the notice of its upcoming Annual General Meeting to shareholders. The AGM is scheduled to take place in London on 9 June 2026, and the ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Poolbeg Pharma advances POLB 001 and obesity pipeline on solid 2025 funding base
Positive
Apr 28, 2026
Poolbeg Pharma reported audited results for 2025, highlighting a year of strong operational and financial progress, including a £7.7 million year-end cash balance and an oversubscribed £4.865 million fundraise that funds the company thro...
Business Operations and StrategyProduct-Related Announcements
Poolbeg wins UK trial clearance as POLB 001 tipped for multi‑billion‑dollar CRS market
Positive
Apr 15, 2026
Poolbeg Pharma has secured UK Medicines and Healthcare products Regulatory Agency authorisation for its POLB 001 TOPICAL trial, clearing the way for patient screening at six NHS sites and keeping interim data on track for release this summer. The ...
Business Operations and Strategy
Poolbeg wins first cancer CRS patent for POLB 001 in Australia
Positive
Mar 31, 2026
Poolbeg Pharma has secured its first national patent grant for cancer immunotherapy-induced Cytokine Release Syndrome from IP Australia, covering the use of any p38 MAPK inhibitor, including lead asset POLB 001, to prevent this serious side effect...
Business Operations and StrategyExecutive/Board Changes
Poolbeg Pharma adds CAR-T veteran Kilcoyne to advisory board to bolster POLB 001 push
Positive
Mar 12, 2026
Poolbeg Pharma has strengthened its scientific leadership by appointing oncology and immunology specialist Dr Adrian Kilcoyne to its Scientific Advisory Board. Kilcoyne, who is Chief Medical Officer at Cellectis and has held senior roles at Celula...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.